Screener
BridgeBio Pharma BBIO Reportable Segment — Total Costs & Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total segment research and development | 126,636 | 111,431 |
| Selling, general and administrative | 163,896 | 106,365 |
| Restructuring, impairment, and related charges | — | 570 |
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — total costs & expenses?
- BridgeBio Pharma (BBIO) reported reportable segment — total costs & expenses of $300.47M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — total costs & expenses changed year-over-year?
- BridgeBio Pharma's reportable segment — total costs & expenses increased by 36.0% year-over-year, from $221.01M to $300.47M.
- What does reportable segment — total costs & expenses mean?
- The aggregate of all operating costs, including cost of revenue, R&D, SG&A, and other segment-specific operating charges. It represents the total burn rate required to maintain the segment's operations.
Ask your AI about BridgeBio Pharma's reportable segment — total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude